03. Treatment outcomes and ethics: bedaquiline
Friday, 04 December 2015, 12:30-13:30

Chair: ID RUUSEN (Canada)

Track: Drug-resistant TB care and treatment, including trials

PC-717-04 The ethics of risk-benefit analysis of new tuberculosis drugs
D Silva, R Upshur, A Dawson (Canada)

PC-718-04 Treatment interruption and directly observed treatment of multidrug-resistant tuberculosis patients in China
X Wei, J Yin, G Zou, Z Zhang, J D Walley, Jose Harwell, Q Sun, Ht Li (Hong Kong, China, UK)

PC-719-04 Compassionate use of bedaquiline: interim outcomes from the Armenian National Tuberculosis Control Office
C Hewison, J Faqirzai, A Hayrapetyan, N Khachatryan, S Qayyum, F Varaine (France, Armenia)

PC-720-04 Is bedaquiline as effective as fluoroquinolones in the treatment of MDR tuberculosis? A microbiological appraisal through a case-control study

PC-721-04 Reasons for not participating in a tuberculosis clinical trial, Lima, Peru 2014
C C Contreras, C Morán, M Lindeborg, Fann Garcia, M Milstein, L Lecca, C Mitnick (Peru, USA)

PC-722-04 Bedaquiline-containing treatment regimens for multidrug-resistant tuberculosis
S Borisov, T Ivanushkina, D Ivanova, N Litvinova, A Filippov (Russian Federation)

PC-723-04 Bedaquiline: new capabilities to treat MDR-TB patients
I Vasilyeva, A. Samoilova, T. Bagdasaryan, V Testov, A. Tikhonov, L Chernousova (Russian Federation)

PC-724-04 Geographical differences in baseline drug resistance patterns and their impact on treatment outcomes in a single-arm bedaquiline phase II trial (C209)
A Pym, A Diacon, F Conradie, S Tang, M Haxaire-Theeuwes, N Lounis, B Van Baelen, B Dannemann (South Africa, Belgium, USA)

PC-725-04 Encouraging early outcomes for individualized treatment of multidrug-resistant tuberculosis using bedaquiline and linezolid in Khayelitsha
E Mohr, H Cox, L Wilkinson, G Van Cutsem, V Cox, J Daniels, O Muller, J Hughes (South Africa)